CSS
IMPL

Cubist Systematic Strategies’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Cubist Systematic Strategies’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-800
Closed -$7K – 3875
2021
Q4 		$7K Buy
+800
New +$7.99K ﹤0.01% 3404

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's IMPL Position: Q1 2022 in Review

Cubist Systematic Strategies sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q1 2022, closing a stake of 800 shares — an estimated $7K sold.

Cubist Systematic Strategies first reported a position in IMPL in Q4 2021 and held it in 1 quarter. The position peaked at $7K in Q4 2021. 42 funds tracked by Wall St. Rank hold IMPL as of Q1 2022.

  • Cubist Systematic Strategies reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 800 Impel Pharmaceuticals Inc. Common Stock shares in Q1 2022, an estimated $7K.
  • Cubist Systematic Strategies first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Cubist Systematic Strategies's Impel Pharmaceuticals Inc. Common Stock position peaked at $7K in Q4 2021.
  • 42 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q1 2022.

Based on Cubist Systematic Strategies's 13F filing for Q1 2022, filed 16 May 2022.